A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

Autor: Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone, Paolo A. Ascierto

Publikováno v: Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-10 (2021)

Abstract Background Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in pat

Externí odkaz: https://doaj.org/article/86e55258d57a4fdc9a2470824a69f5e9

Pregnancy-Induced Alterations in NK Cell Phenotype and Function

Autor: Mathieu Le Gars, Christof Seiler, Alexander W. Kay, Nicholas L. Bayless, Elina Starosvetsky, Lindsay Moore, Shai S. Shen-Orr, Natali Aziz, Purvesh Khatri, Cornelia L. Dekker, Gary E. Swan, Mark M. Davis, Susan Holmes, Catherine A. Blish

Publikováno v: Frontiers in Immunology, Vol 10 (2019)

Pregnant women are particularly susceptible to complications of influenza A virus infection, which may result from pregnancy-induced changes in the function of immune cells, including natural killer (NK) cells. To better understand NK cell function d

Externí odkaz: https://doaj.org/article/3ebfba4f605d4fb48eb479e2c9e2771d

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

Autor: Arlene H. Sharpe, Lisa H. Butterfield, Christian A Koch, Elizabeth M. Jaffee, Nicholas L. Bayless, Samantha Bucktrout, William J. Murphy, Theresa L. Walunas, Jeffrey A. Bluestone, Alexandra-Chloé Villani, Bart O. Roep

Publikováno v: Journal for immunotherapy of cancer, vol 9, iss 9
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer

Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are wel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ab342dfeba65ccc9a7d1906875d8ce8
https://escholarship.org/uc/item/47n8s5f9

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Autor: Jacob Glanville, Nicholas L. Bayless, Sarah Ives, Sawsan Youssef, Keith Glanville, Erwin Calgua, Karina Reyna Peñate, Rachel Hovde, Jean-Philippe Bürckert, Christina Pettus, Devanshi Shanghavi

Rapidly evolving pathogens pose a challenge to vaccine design, as their mutations render previous vaccine responses obsolete. For influenza, conserved epitopes on the viral coat proteins have been identified, but mysteriously they are missed by the a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::198eca360af1885e1253a3dcbd0d5d85
https://doi.org/10.21203/rs.3.rs-100459/v1

Feasibility and utility of synthetic control arms derived from real-world data to support clinical development

Autor: Jaclyn Paige Lyman, Abigail Doucette, Binbin Zheng-Lin, Christopher R. Cabanski, Molly A. Maloy, Nicholas L. Bayless, Jingying Xu, William Smith, Joyson Joseph Karakunnel, Justin P. Fairchild, Ramy Ibrahim, Eileen Mary O'Reilly, Robert H. Vonderheide, Peter Edward Gabriel

Publikováno v: Journal of Clinical Oncology. 40:528-528

528 Background: ‘Synthetic’ control arms (SCAs), created using electronic health records (EHRs), have immense potential to augment clinical trial findings and provide a rich context of real-world evidence (RWE) while reducing patient (pt) and spo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f075541c315e1bd01159cc7d184701e8
https://doi.org/10.1200/jco.2022.40.4_suppl.528